Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease

<p>Abstract</p> <p>Background</p> <p>Huntington's disease (HD) is an inherited neurogenerative disease caused by an abnormal expansion of glutamine repeats in the huntingtin protein. There is currently no treatment to prevent the neurodegeneration caused by this de...

Full description

Bibliographic Details
Main Authors: Pineda Jose R, Pardo Raúl, Zala Diana, Yu Hua, Humbert Sandrine, Saudou Frédéric
Format: Article
Language:English
Published: BMC 2009-10-01
Series:Molecular Brain
Online Access:http://www.molecularbrain.com/content/2/1/33
_version_ 1811284858308132864
author Pineda Jose R
Pardo Raúl
Zala Diana
Yu Hua
Humbert Sandrine
Saudou Frédéric
author_facet Pineda Jose R
Pardo Raúl
Zala Diana
Yu Hua
Humbert Sandrine
Saudou Frédéric
author_sort Pineda Jose R
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Huntington's disease (HD) is an inherited neurogenerative disease caused by an abnormal expansion of glutamine repeats in the huntingtin protein. There is currently no treatment to prevent the neurodegeneration caused by this devastating disorder. Huntingtin has been shown to be a positive regulator of vesicular transport, particularly for neurotrophins such as brain-derived neurotrophic factor (BDNF). This function is lost in patients with HD, resulting in a decrease in neurotrophic support and subsequent neuronal death. One promising line of treatment is therefore the restoration of huntingtin function in BDNF transport.</p> <p>Results</p> <p>The phosphorylation of huntingtin at serine 421 (S421) restores its function in axonal transport. We therefore investigated whether inhibition of calcineurin, the <it>bona fide </it>huntingtin S421 phosphatase, restored the transport defects observed in HD. We found that pharmacological inhibition of calcineurin by FK506 led to sustained phosphorylation of mutant huntingtin at S421. FK506 restored BDNF transport in two complementary models: rat primary neuronal cultures expressing mutant huntingtin and mouse cortical neurons from <it>Hdh</it><sup>Q111/Q111 </sup>HD knock-in mice. This effect was the result of specific calcineurin inhibition, as calcineurin silencing restored both anterograde and retrograde transport in neurons from <it>Hdh</it><sup>Q111/Q111 </sup>mice. We also observed a specific increase in calcineurin activity in the brain of <it>Hdh</it><sup>Q111/Q111 </sup>mice potentially accounting for the selective loss of huntingtin phosphorylation and contributing to neuronal cell death in HD.</p> <p>Conclusion</p> <p>Our results validate calcineurin as a target for the treatment of HD and provide the first demonstration of the restoration of huntingtin function by an FDA-approved compound.</p>
first_indexed 2024-04-13T02:35:53Z
format Article
id doaj.art-9bf3d31bf60249f9849bae539253819d
institution Directory Open Access Journal
issn 1756-6606
language English
last_indexed 2024-04-13T02:35:53Z
publishDate 2009-10-01
publisher BMC
record_format Article
series Molecular Brain
spelling doaj.art-9bf3d31bf60249f9849bae539253819d2022-12-22T03:06:22ZengBMCMolecular Brain1756-66062009-10-01213310.1186/1756-6606-2-33Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's diseasePineda Jose RPardo RaúlZala DianaYu HuaHumbert SandrineSaudou Frédéric<p>Abstract</p> <p>Background</p> <p>Huntington's disease (HD) is an inherited neurogenerative disease caused by an abnormal expansion of glutamine repeats in the huntingtin protein. There is currently no treatment to prevent the neurodegeneration caused by this devastating disorder. Huntingtin has been shown to be a positive regulator of vesicular transport, particularly for neurotrophins such as brain-derived neurotrophic factor (BDNF). This function is lost in patients with HD, resulting in a decrease in neurotrophic support and subsequent neuronal death. One promising line of treatment is therefore the restoration of huntingtin function in BDNF transport.</p> <p>Results</p> <p>The phosphorylation of huntingtin at serine 421 (S421) restores its function in axonal transport. We therefore investigated whether inhibition of calcineurin, the <it>bona fide </it>huntingtin S421 phosphatase, restored the transport defects observed in HD. We found that pharmacological inhibition of calcineurin by FK506 led to sustained phosphorylation of mutant huntingtin at S421. FK506 restored BDNF transport in two complementary models: rat primary neuronal cultures expressing mutant huntingtin and mouse cortical neurons from <it>Hdh</it><sup>Q111/Q111 </sup>HD knock-in mice. This effect was the result of specific calcineurin inhibition, as calcineurin silencing restored both anterograde and retrograde transport in neurons from <it>Hdh</it><sup>Q111/Q111 </sup>mice. We also observed a specific increase in calcineurin activity in the brain of <it>Hdh</it><sup>Q111/Q111 </sup>mice potentially accounting for the selective loss of huntingtin phosphorylation and contributing to neuronal cell death in HD.</p> <p>Conclusion</p> <p>Our results validate calcineurin as a target for the treatment of HD and provide the first demonstration of the restoration of huntingtin function by an FDA-approved compound.</p>http://www.molecularbrain.com/content/2/1/33
spellingShingle Pineda Jose R
Pardo Raúl
Zala Diana
Yu Hua
Humbert Sandrine
Saudou Frédéric
Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease
Molecular Brain
title Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease
title_full Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease
title_fullStr Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease
title_full_unstemmed Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease
title_short Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease
title_sort genetic and pharmacological inhibition of calcineurin corrects the bdnf transport defect in huntington s disease
url http://www.molecularbrain.com/content/2/1/33
work_keys_str_mv AT pinedajoser geneticandpharmacologicalinhibitionofcalcineurincorrectsthebdnftransportdefectinhuntingtonsdisease
AT pardoraul geneticandpharmacologicalinhibitionofcalcineurincorrectsthebdnftransportdefectinhuntingtonsdisease
AT zaladiana geneticandpharmacologicalinhibitionofcalcineurincorrectsthebdnftransportdefectinhuntingtonsdisease
AT yuhua geneticandpharmacologicalinhibitionofcalcineurincorrectsthebdnftransportdefectinhuntingtonsdisease
AT humbertsandrine geneticandpharmacologicalinhibitionofcalcineurincorrectsthebdnftransportdefectinhuntingtonsdisease
AT saudoufrederic geneticandpharmacologicalinhibitionofcalcineurincorrectsthebdnftransportdefectinhuntingtonsdisease